Evidence map›Paper›PMID 33268457›Full record

ArticleThorax2021

Topographic heterogeneity of lung microbiota in end-stage idiopathic pulmonary fibrosis: the Microbiome in Lung Explants-2 (MiLEs-2) study.

Eleanor Valenzi, Haopu Yang, John C Sembrat, Libing Yang, Spencer Winters, Rachel Nettles, Daniel J Kass, Shulin Qin, Xiaohong Wang, Michael M Myerburg and 8 more

Abstract read
In one paragraph

Article in Thorax, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers.

0numbers the graph read from it
0cells of the map it votes in
16citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

16 citing papers in PubMed.

  1. Review
  2. Hallmarks of the ageing lung: 10 years later.The European respiratory journal · 2026
    Review
  3. Article
  4. Review
  5. Article
  6. Donor LungAmerican journal of respiratory cell and molecular biology · 2025
    Article
  7. Review
  8. From commensalism to pathogenesis: the hidden role of the respiratory virome.Frontiers in cellular and infection microbiology · 2025
    Review
  9. Review
  10. Review
  11. Review
  12. Article
  13. The lung microbiome: progress and promise.The Journal of clinical investigation · 2021
    Review
  14. Review
  15. Article
  16. The evolving role of the lung microbiome in pulmonary fibrosis.American journal of physiology. Lung cellular and molecular physiology · 2020
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

18 authors.

Eleanor ValenziDivision of Pulmonary, Allergy and Critical Care Medicine, Department of Medicine, University of Pittsburgh Medical Center, Pittsburgh, Pennsylvania, USA.
Haopu YangCenter for Medicine and the Microbiome, University of Pittsburgh, Pittsburgh, Pennsylvania, USA.ORCID 0000-0001-6858-1778
John C SembratDivision of Pulmonary, Allergy and Critical Care Medicine, Department of Medicine, University of Pittsburgh Medical Center, Pittsburgh, Pennsylvania, USA.
Libing YangCenter for Medicine and the Microbiome, University of Pittsburgh, Pittsburgh, Pennsylvania, USA.
Spencer WintersDivision of Pulmonary, Allergy and Critical Care Medicine, Department of Medicine, University of Pittsburgh Medical Center, Pittsburgh, Pennsylvania, USA.
Rachel NettlesCenter for Medicine and the Microbiome, University of Pittsburgh, Pittsburgh, Pennsylvania, USA.
Daniel J KassDivision of Pulmonary, Allergy and Critical Care Medicine, Department of Medicine, University of Pittsburgh Medical Center, Pittsburgh, Pennsylvania, USA.
Shulin QinDivision of Pulmonary, Allergy and Critical Care Medicine, Department of Medicine, University of Pittsburgh Medical Center, Pittsburgh, Pennsylvania, USA.
Xiaohong WangDivision of Pulmonary, Allergy and Critical Care Medicine, Department of Medicine, University of Pittsburgh Medical Center, Pittsburgh, Pennsylvania, USA.
Michael M MyerburgDivision of Pulmonary, Allergy and Critical Care Medicine, Department of Medicine, University of Pittsburgh Medical Center, Pittsburgh, Pennsylvania, USA.
Barbara MethéDivision of Pulmonary, Allergy and Critical Care Medicine, Department of Medicine, University of Pittsburgh Medical Center, Pittsburgh, Pennsylvania, USA.
Adam FitchDivision of Pulmonary, Allergy and Critical Care Medicine, Department of Medicine, University of Pittsburgh Medical Center, Pittsburgh, Pennsylvania, USA.
Jonathan K AlderDivision of Pulmonary, Allergy and Critical Care Medicine, Department of Medicine, University of Pittsburgh Medical Center, Pittsburgh, Pennsylvania, USA.
Panayiotis V BenosDepartment of Computational and Systems Biology, University of Pittsburgh, Pittsburgh, Pennsylvania, USA.ORCID 0000-0003-3172-3132
Bryan J McVerryDivision of Pulmonary, Allergy and Critical Care Medicine, Department of Medicine, University of Pittsburgh Medical Center, Pittsburgh, Pennsylvania, USA.
Mauricio RojasDivision of Pulmonary, Allergy and Critical Care Medicine, Department of Medicine, University of Pittsburgh Medical Center, Pittsburgh, Pennsylvania, USA.ORCID 0000-0001-7340-4784
Alison MorrisDivision of Pulmonary, Allergy and Critical Care Medicine, Department of Medicine, University of Pittsburgh Medical Center, Pittsburgh, Pennsylvania, USA.
Georgios D KitsiosDivision of Pulmonary, Allergy and Critical Care Medicine, Department of Medicine, University of Pittsburgh Medical Center, Pittsburgh, Pennsylvania, USA kitsiosg@upmc.edu.ORCID 0000-0002-1018-948X

Funding

Translational Training Program in Pulmonary Biology and MedicineT32HL007563 · NHLBI · UNIVERSITY OF PITTSBURGH AT PITTSBURGH · PI Melanie Koenigshoff · 1985 to 2026
$12.3M
Genomic Analysis of Tissue and Cellular Heterogeneity in IPFR01HL127349 · NHLBI · YALE UNIVERSITY · PI BENOS, PANAGIOTIS V, KAMINSKI, NAFTALI · 2015 to 2025
$5.9M
Mechanisms of Telomere-Mediated Lung DiseaseR01HL135062 · NHLBI · UNIVERSITY OF PITTSBURGH AT PITTSBURGH · PI Jonathan K. Alder · 2018 to 2026
$4.1M
Pathogenesis of Obstruction/Emphysema and the Microbiome (POEM) in HIVU01HL098962 · NHLBI · UNIVERSITY OF PITTSBURGH AT PITTSBURGH · PI GHEDIN, ELODIE, MORRIS, ALISON · 2009 to 2013
$3.8M
Aging of Mesenchymal Stem Cells Missing Link in IPFR01HL123766 · NHLBI · UNIVERSITY OF PITTSBURGH AT PITTSBURGH · PI ROJAS, MAURICIO · 2015 to 2018
$1.9M
Twist1 subphenotypes and pulmonary fibrosisR01HL126990 · NHLBI · UNIVERSITY OF PITTSBURGH AT PITTSBURGH · PI KASS, DANIEL J · 2015 to 2019
$1.9M
Systems Level Causal Discovery in Heterogeneous TOPMed DataU01HL137159 · NHLBI · UNIVERSITY OF PITTSBURGH AT PITTSBURGH · PI BENOS, PANAGIOTIS V, SCIURBA, FRANK · 2017 to 2019
$1.8M
Microbiome-based diagnosis of pneumonia in the acute respiratory distress syndromeK23HL139987 · NHLBI · UNIVERSITY OF PITTSBURGH AT PITTSBURGH · PI KITSIOS, GEORGIOS · 2018 to 2022
$806k
Mentoring and Patient-Oriented Research in HIV Obstructive Lung DiseaseK24HL123342 · NHLBI · UNIVERSITY OF PITTSBURGH AT PITTSBURGH · PI MORRIS, ALISON · 2014 to 2018
$571k
NHLBI NIH HHS K23 HL139987NHLBI NIH HHS K24 HL123342NHLBI NIH HHS R01 HL123766NHLBI NIH HHS R01 HL126990NHLBI NIH HHS R01 HL127349NHLBI NIH HHS R01 HL135062NHLBI NIH HHS T32 HL007563NHLBI NIH HHS U01 HL098962NHLBI NIH HHS U01 HL137159
6 · The paper itself

Abstract

backgroundLung microbiota profiles in patients with early idiopathic pulmonary fibrosis (IPF) have been associated with disease progression; however, the topographic heterogeneity of lung microbiota and their roles in advanced IPF are unknown.

methodsWe performed a retrospective, case-control study of explanted lung tissue obtained at the time of lung transplantation or rapid autopsy from patients with IPF and other chronic lung diseases (connective tissue disease-associated interstitial lung disease (CTD-ILD), cystic fibrosis (CF), COPD and donor lungs unsuitable for transplant from Center for Organ Recovery and Education (CORE)). We sampled subpleural tissue and airway-based specimens (bronchial washings and airway tissue) and quantified bacterial load and profiled communities by amplification and sequencing of the 16S rRNA gene.

findingsExplants from 62 patients with IPF, 15 patients with CTD-ILD, 20 patients with CF, 20 patients with COPD and 20 CORE patients were included. Airway-based samples had higher bacterial load compared with distal parenchymal tissue. IPF basilar tissue had much lower bacterial load compared with CF and CORE lungs (p<0.001). No microbial community differences were found between parenchymal tissue samples from different IPF lobes. Dirichlet multinomial models revealed an IPF cluster (29%) with distinct composition, high bacterial load and low alpha diversity, exhibiting higher odds for acute exacerbation or death.

interpretationIPF explants had low biomass in the distal parenchyma of all three lobes with higher bacterial load in the airways. The discovery of a distinct subgroup of patients with IPF with higher bacterial load and worse clinical outcomes supports investigation of personalised medicine approaches for microbiome-targeted interventions.

Indexed as

Lung TransplantationAdultAgedBronchoalveolar Lavage FluidCase-Control StudiesDisease ProgressionHumansIdiopathic Pulmonary FibrosisLungMicrobiotaMiddle AgedRetrospective StudiesTomography, X-Ray ComputedYoung Adultbacterial infectionidiopathic pulmonary fibrosislung transplantation

Identifiers

PMID33268457
PMCPMC8203183

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.